Solventum Corporation (NYSE:SOLV) Stock Has Consensus Price Target of $92.80

Shares of Solventum Corporation (NYSE:SOLV) have received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $92.80.

A number of brokerages have recently commented on SOLV. Stifel Nicolaus raised their target price on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. KeyCorp boosted their price target on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a report on Saturday, September 12th. UBS Group lifted their target price on Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th.

Solventum Stock Down 0.5%

Shares of SOLV opened at $87.73 on Friday. The firm has a market capitalization of $14.93 billion, a P/E ratio of 10.73, a P/E/G ratio of 1.38 and a beta of 0.64. Solventum has a 12-month low of $62.38 and a 12-month high of $94.16. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The firm has a fifty day moving average price of $88.24 and a 200-day moving average price of $78.36.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts expect that Solventum will post 7.22 earnings per share for the current year.

Institutional Trading of Solventum

Institutional investors and hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC raised its stake in Solventum by 2.2% in the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock valued at $438,000 after buying an additional 144 shares during the last quarter. Deseret Mutual Benefit Administrators grew its stake in shares of Solventum by 39.5% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 516 shares of the company’s stock worth $41,000 after acquiring an additional 146 shares during the last quarter. HB Wealth Management LLC grew its stake in shares of Solventum by 3.5% during the first quarter. HB Wealth Management LLC now owns 4,292 shares of the company’s stock worth $280,000 after acquiring an additional 147 shares during the last quarter. Clearstead Trust LLC increased its holdings in shares of Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after acquiring an additional 150 shares in the last quarter. Finally, Empirical Finance LLC increased its holdings in shares of Solventum by 3.6% during the second quarter. Empirical Finance LLC now owns 5,074 shares of the company’s stock valued at $391,000 after acquiring an additional 174 shares in the last quarter.

About Solventum

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products, technologies and services designed to support clinical care, healthcare operations and patient outcomes. The company serves healthcare providers, dental professionals, laboratories, manufacturers and other organizations.

Solventum’s portfolio includes medical and surgical products such as wound-care systems, surgical drapes, sterilization and infection-prevention solutions, and patient-monitoring or fixation products.